Therapeutic effect of pioglitazone on chronic kidney disease (CKD).

UMIN ID: UMIN000001017

Registered date:27/02/2008

Basic Information

• Recruitment status: Complete: follow-up complete
• Health condition(s) or Problem(s) studied: chronic kidney disease (CKD)
• Date of first enrollment: 2008/02/01
• Target sample size: 24
• Countries of recruitment: Japan
• Study type: Interventional

Intervention(s)

Patients of intervention group are treated with pioglitazone orally from the dose of 15mg/day, increased up to 30-45mg/day within one month, and continued for 6 month. The efficacy and side effects are evaluated.
Patients of control group are treated with dipyridamole orally from the dose of 150mg/day, increased up to 300mg/day within one month, and continued for 6 month. The efficacy and side effects are compared with intervention group.

Outcome(s)

• Primary Outcome: Decrease in levels of proteinuria
• Secondary Outcome: Inhibition of deterioration in renal function (serum creatinine, estimated-GFR)

Key inclusion & exclusion criteria

• Age minimum: 20years-old
• Age maximum: 85years-old
• Gender: Male and Female
• Exclude criteria: 1. Chronic renal failure with serum creatinine level above 3.0 mg/dl. 2. Severe liver dysfunction. 3. Severe edema or chronic heart failure. 4. Past history of allergy against pioglitazone. 5. Pregnant or breast feeding patients. 6. Patients with ongoing steroid therapy.

Related Information

• Primary Sponsor: National Defense Medical College
• Source(s) of Monetary Support: None